LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

15.59 5.34

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.83

Максимум

16.24

Ключови измерители
By Trading Economics
Приходи	35M 9.5M
Продажби	35M 94M
EPS	0.06
Марж на печалбата	10.158
Служители	619
EBITDA	35M 17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+34.92% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-358M 2.3B
Предишно отваряне	10.25
Предишно затваряне	15.59

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.12.2025 г., 22:13 ч. UTC

Печалби

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9.12.2025 г., 21:40 ч. UTC

Печалби

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9.12.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9.12.2025 г., 16:57 ч. UTC

Значими двигатели на пазара

Clear Secure Rises on Medicare Identity Verification Contract

9.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9.12.2025 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings Stake in Lenovo Now at 32.34%

9.12.2025 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9.12.2025 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9.12.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9.12.2025 г., 22:42 ч. UTC

Печалби

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9.12.2025 г., 20:28 ч. UTC

Пазарно говорене

Oil Futures Decline for Second Straight Session -- Market Talk

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Reports Voting Results From Special Meeting of Hldrs

9.12.2025 г., 20:26 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9.12.2025 г., 20:21 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9.12.2025 г., 19:52 ч. UTC

Печалби

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9.12.2025 г., 19:17 ч. UTC

Печалби

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.12.2025 г., 17:11 ч. UTC

Печалби

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

34.92% нагоре

12-месечна прогноза

Среден 20.17 USD 34.92%

Висок 22 USD

Нисък 18 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.